Kestra Private Wealth Services LLC Invests $222,000 in BioNTech SE (NASDAQ:BNTX)

Kestra Private Wealth Services LLC bought a new position in shares of BioNTech SE (NASDAQ:BNTXGet Rating) in the 1st quarter, Holdings Channel reports. The fund bought 1,304 shares of the company’s stock, valued at approximately $222,000.

A number of other institutional investors and hedge funds have also bought and sold shares of BNTX. Synovus Financial Corp boosted its holdings in shares of BioNTech by 15.4% during the fourth quarter. Synovus Financial Corp now owns 2,990 shares of the company’s stock worth $771,000 after acquiring an additional 400 shares during the period. Exane Derivatives increased its stake in shares of BioNTech by 18.1% during the first quarter. Exane Derivatives now owns 704 shares of the company’s stock worth $120,000 after purchasing an additional 108 shares during the period. Cantor Fitzgerald L. P. acquired a new stake in BioNTech during the 1st quarter worth approximately $223,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in BioNTech by 58.9% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,257 shares of the company’s stock valued at $4,308,000 after purchasing an additional 9,364 shares during the period. Finally, Primecap Management Co. CA grew its holdings in BioNTech by 1.3% in the 1st quarter. Primecap Management Co. CA now owns 4,242,068 shares of the company’s stock valued at $723,527,000 after buying an additional 54,950 shares in the last quarter. Institutional investors and hedge funds own 13.77% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BNTX shares. Cowen began coverage on BioNTech in a report on Wednesday, August 17th. They set a “market perform” rating for the company. Canaccord Genuity Group lifted their price objective on shares of BioNTech from $192.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Cowen assumed coverage on shares of BioNTech in a research report on Wednesday, August 17th. They set a “market perform” rating and a $177.00 target price on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $192.00 price target on shares of BioNTech in a research report on Wednesday, July 6th. Finally, HC Wainwright reduced their price target on BioNTech from $283.00 to $272.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, BioNTech presently has an average rating of “Hold” and an average price target of $231.43.

BioNTech Price Performance

BioNTech stock opened at $128.24 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.06 and a current ratio of 5.15. BioNTech SE has a 52 week low of $117.08 and a 52 week high of $374.58. The stock has a market capitalization of $31.12 billion, a P/E ratio of 2.48 and a beta of 0.03. The stock has a fifty day moving average of $154.04 and a 200-day moving average of $154.72.

BioNTech (NASDAQ:BNTXGet Rating) last released its earnings results on Monday, August 8th. The company reported $6.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.08 by ($0.63). The business had revenue of $3.20 billion during the quarter, compared to the consensus estimate of $4.11 billion. BioNTech had a net margin of 55.43% and a return on equity of 88.76%. The business’s revenue was down 39.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $12.98 EPS. On average, sell-side analysts expect that BioNTech SE will post 33.27 earnings per share for the current fiscal year.

BioNTech Profile

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Featured Stories

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTXGet Rating).

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.